Radiation therapy of renal cell carcinoma skeletal metastases – Does histologic subtype predict progression?

Introduction: This investigation assessed whether the following factors were associated with radiographic local progression in bone metastases from renal cell carcinoma (RCC): (1) high-risk histologic features (2) lesional surgery (3) biologically effective dose (BED) of radiation therapy. Methods a...

Full description

Saved in:
Bibliographic Details
Main Authors: Kavin Sundaram, Joshua M. Lawrenz, Precious C. Oyem, Aditya Banerjee, Shannon Wu, Paras Shah, Shireen Parsai, Chirag Shah, Nathan W. Mesko, John Reith, Lukas M. Nystrom
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Clinical Surgical Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2773160X24000084
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850060690615697408
author Kavin Sundaram
Joshua M. Lawrenz
Precious C. Oyem
Aditya Banerjee
Shannon Wu
Paras Shah
Shireen Parsai
Chirag Shah
Nathan W. Mesko
John Reith
Lukas M. Nystrom
author_facet Kavin Sundaram
Joshua M. Lawrenz
Precious C. Oyem
Aditya Banerjee
Shannon Wu
Paras Shah
Shireen Parsai
Chirag Shah
Nathan W. Mesko
John Reith
Lukas M. Nystrom
author_sort Kavin Sundaram
collection DOAJ
description Introduction: This investigation assessed whether the following factors were associated with radiographic local progression in bone metastases from renal cell carcinoma (RCC): (1) high-risk histologic features (2) lesional surgery (3) biologically effective dose (BED) of radiation therapy. Methods and materials: A single-institution database identified all patients who underwent surgery and radiation therapy for bone metastases from RCC to the appendicular skeleton and pelvis from 2006 to 2016. Thirty-six patients underwent radiotherapy for 80 metastases. While all patients had surgical stabilization, 17/36 also had lesional surgery to address the metastatic lesion. Progression of each individual lesion was determined using the application of RECIST criteria to imaging at last follow-up. Results: The rate of progressive disease was 8/25 (32%) in the high-risk group versus 5/55 (9%) in the standard-risk group (p ​= ​0.019). The rate of progression among high-risk metastases undergoing lesional surgery was 0/9 versus 8/16 (50%) having non-lesional surgery (p ​= ​0.0218). The rate of progression among standard-risk metastases undergoing lesional surgery was 1/16 (6%) versus 4/39 (10%) with non-lesional surgery (p ​= ​1.00). High-risk histologic features (OR: 10.592, 95% confidence interval: 1.347–83.271, p ​= ​0.025) and as well as a reduction in risk with every additional Gray of BED (OR: 0.902, 95% confidence interval: 0.827–0.984, p ​= ​0.021) were found to predict progressive disease. Conclusions: Bone metastases from renal cell carcinoma with high-risk histologic features are associated with less favorable response to radiotherapy than those with standard-risk histology. Delivery of a higher BED was associated with lower odds of progression.
format Article
id doaj-art-b3554a0033aa4eec8dc84952aa394c47
institution DOAJ
issn 2773-160X
language English
publishDate 2024-03-01
publisher Elsevier
record_format Article
series Clinical Surgical Oncology
spelling doaj-art-b3554a0033aa4eec8dc84952aa394c472025-08-20T02:50:29ZengElsevierClinical Surgical Oncology2773-160X2024-03-013110004010.1016/j.cson.2024.100040Radiation therapy of renal cell carcinoma skeletal metastases – Does histologic subtype predict progression?Kavin Sundaram0Joshua M. Lawrenz1Precious C. Oyem2Aditya Banerjee3Shannon Wu4Paras Shah5Shireen Parsai6Chirag Shah7Nathan W. Mesko8John Reith9Lukas M. Nystrom10Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA; University of Texas at Austin Dell Medical School, 1501 Red River St., Austin, TX 78712, USAVanderbilt University Medical Center, 1215 21st Ave S, Medical Center East, Suite 4200, Nashville, TN, 37232, USACleveland Clinic Lerner College of Medicine of Case Western University, 9501 Euclid Ave./EC10, Cleveland, OH, 44195, USACleveland Clinic Lerner College of Medicine of Case Western University, 9501 Euclid Ave./EC10, Cleveland, OH, 44195, USACleveland Clinic Lerner College of Medicine of Case Western University, 9501 Euclid Ave./EC10, Cleveland, OH, 44195, USACleveland Clinic Lerner College of Medicine of Case Western University, 9501 Euclid Ave./EC10, Cleveland, OH, 44195, USARiverside Radiation Onc Dept., 3535 Olentangy River Rd, Columbus, OH, 43214, USACleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USACleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USACleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USACleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA; Corresponding author.Introduction: This investigation assessed whether the following factors were associated with radiographic local progression in bone metastases from renal cell carcinoma (RCC): (1) high-risk histologic features (2) lesional surgery (3) biologically effective dose (BED) of radiation therapy. Methods and materials: A single-institution database identified all patients who underwent surgery and radiation therapy for bone metastases from RCC to the appendicular skeleton and pelvis from 2006 to 2016. Thirty-six patients underwent radiotherapy for 80 metastases. While all patients had surgical stabilization, 17/36 also had lesional surgery to address the metastatic lesion. Progression of each individual lesion was determined using the application of RECIST criteria to imaging at last follow-up. Results: The rate of progressive disease was 8/25 (32%) in the high-risk group versus 5/55 (9%) in the standard-risk group (p ​= ​0.019). The rate of progression among high-risk metastases undergoing lesional surgery was 0/9 versus 8/16 (50%) having non-lesional surgery (p ​= ​0.0218). The rate of progression among standard-risk metastases undergoing lesional surgery was 1/16 (6%) versus 4/39 (10%) with non-lesional surgery (p ​= ​1.00). High-risk histologic features (OR: 10.592, 95% confidence interval: 1.347–83.271, p ​= ​0.025) and as well as a reduction in risk with every additional Gray of BED (OR: 0.902, 95% confidence interval: 0.827–0.984, p ​= ​0.021) were found to predict progressive disease. Conclusions: Bone metastases from renal cell carcinoma with high-risk histologic features are associated with less favorable response to radiotherapy than those with standard-risk histology. Delivery of a higher BED was associated with lower odds of progression.http://www.sciencedirect.com/science/article/pii/S2773160X24000084Renal cell carcinomaBony metastasisSarcomatoidRhabdoidHistologyRadiation
spellingShingle Kavin Sundaram
Joshua M. Lawrenz
Precious C. Oyem
Aditya Banerjee
Shannon Wu
Paras Shah
Shireen Parsai
Chirag Shah
Nathan W. Mesko
John Reith
Lukas M. Nystrom
Radiation therapy of renal cell carcinoma skeletal metastases – Does histologic subtype predict progression?
Clinical Surgical Oncology
Renal cell carcinoma
Bony metastasis
Sarcomatoid
Rhabdoid
Histology
Radiation
title Radiation therapy of renal cell carcinoma skeletal metastases – Does histologic subtype predict progression?
title_full Radiation therapy of renal cell carcinoma skeletal metastases – Does histologic subtype predict progression?
title_fullStr Radiation therapy of renal cell carcinoma skeletal metastases – Does histologic subtype predict progression?
title_full_unstemmed Radiation therapy of renal cell carcinoma skeletal metastases – Does histologic subtype predict progression?
title_short Radiation therapy of renal cell carcinoma skeletal metastases – Does histologic subtype predict progression?
title_sort radiation therapy of renal cell carcinoma skeletal metastases does histologic subtype predict progression
topic Renal cell carcinoma
Bony metastasis
Sarcomatoid
Rhabdoid
Histology
Radiation
url http://www.sciencedirect.com/science/article/pii/S2773160X24000084
work_keys_str_mv AT kavinsundaram radiationtherapyofrenalcellcarcinomaskeletalmetastasesdoeshistologicsubtypepredictprogression
AT joshuamlawrenz radiationtherapyofrenalcellcarcinomaskeletalmetastasesdoeshistologicsubtypepredictprogression
AT preciouscoyem radiationtherapyofrenalcellcarcinomaskeletalmetastasesdoeshistologicsubtypepredictprogression
AT adityabanerjee radiationtherapyofrenalcellcarcinomaskeletalmetastasesdoeshistologicsubtypepredictprogression
AT shannonwu radiationtherapyofrenalcellcarcinomaskeletalmetastasesdoeshistologicsubtypepredictprogression
AT parasshah radiationtherapyofrenalcellcarcinomaskeletalmetastasesdoeshistologicsubtypepredictprogression
AT shireenparsai radiationtherapyofrenalcellcarcinomaskeletalmetastasesdoeshistologicsubtypepredictprogression
AT chiragshah radiationtherapyofrenalcellcarcinomaskeletalmetastasesdoeshistologicsubtypepredictprogression
AT nathanwmesko radiationtherapyofrenalcellcarcinomaskeletalmetastasesdoeshistologicsubtypepredictprogression
AT johnreith radiationtherapyofrenalcellcarcinomaskeletalmetastasesdoeshistologicsubtypepredictprogression
AT lukasmnystrom radiationtherapyofrenalcellcarcinomaskeletalmetastasesdoeshistologicsubtypepredictprogression